GemPharmatech’s Post

Come find us at #AACR2024 to see how protein sequencing can enhance your cancer research! #QSI #quantumsi #Platinum #proteinsequencing #protein #cancer

🎯Exciting news from AACR 2024! mProbe Inc. presented groundbreaking findings on the expression distribution of #ADC target #Her3, #EGFR, #TROP2, #FRalpha, #gPNMB, and the endocytosis-related protein #CAV-1 across different #HER2 subgroups. These insights highlight the unique protein expression and molecular characteristics observed in each cancer type. Leveraging mass spectrometry #SRM, the study quantified 72 protein biomarkers synchronously from 2-3 FFPE slices, offering valuable insights for the development of dual-targeting #ADC therapies.

🚀 New Research Publication! 🚀 I’m excited to share our latest study just published in ACS Nano, which reveals a novel way to strengthen protein complexes, potentially revolutionizing cancer therapies. 🧬✨ In collaboration with Michael A. Nash and Byeongseon Yang from the University of Basel, we investigated the interaction between PD-L1 and a small scaffold protein known as Affibody. PD-L1 is crucial in allowing tumors to evade the immune system and has become a major target in cancer treatments. By enhancing the stability and strength of this protein complex, we demonstrated its potential as a more effective carrier for cancer-fighting drugs. Using advanced techniques, we made these complexes up to 4x stronger, significantly improving drug delivery systems. This research not only highlights our commitment to advancing healthcare through innovative science but also opens new avenues for optimizing bioconjugation strategies, potentially leading to more efficient and targeted therapies for various diseases. 📖 Read the full study: https://lnkd.in/eJ4atC7v #CancerResearch #PDL1 #Affibody #HealthcareInnovation #ProteinEngineering #Biotechnology

🔬 Exciting insights were unveiled at AACR 2024! Dr. Sheeno Thyparambil, PhD presented mProbe's co-expression #proteomic analysis of #ADC receptor and payload biomarkers, including #TROP2, in #BreastCancer. Our study explored the unique protein expression patterns in different #HER2 subgroups, offering crucial insights for the development of dual-targeting #ADC therapies. ✨ The potential of #proteomic analysis was unlocked! By quantifying 72 protein biomarkers from just 2-3 FFPE slices, mProbe shed light on the co-expression patterns of ADC target antigens and payload-related proteins, paving the way for innovative dual-targeting #ADC #drug development. 🌟 #PersonalizedMedicine was in action! mProbe's study underscored the importance of tailored approaches in cancer treatment. Our findings highlighted distinct protein expression and molecular characteristics in different cancer types, crucial for optimizing therapeutic strategies and advancing precision medicine. 🎯 #AACR #BreastCancer #Proteomics #HER2 #ADC #CancerDrug #TROP2 #CancerResearch #PersonalizedMedicine #PrecisionOncology #mProbe #OncoOmicsDx

Proteomics holds great promise for cancer immunotherapy, with intensive efforts being exerted for the early identification of disease, selection of patients likely to respond, and prediction of adverse events . Despite this potential, the high cost and low throughput of existing tools to profile circulating proteins render such studies prohibitively slow and costly, and limit their wide-spread application. In a poster presented on 📍Friday Nov 8th by Nathaniel Robichaud, PhD, Scientific Partnership Lead at Nomic, we present proof-of-concept results leveraging a novel proteomics tool, the nELISA, to identify cancer biomarkers and inflammatory indicators in a low-cost, high-throughput manner. Read the abstract here: https://hubs.ly/Q02X9s1S0 #proteinprofiling #proteomics #SITC #nomic #nelisa #

🚀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝗢𝘂𝗿 𝗡𝗲𝘄 𝗜𝗻𝗳𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰! 🧬 Explore the transformative role of extracellular vesicles (EVs) in cancer diagnosis and treatment. Our infographic highlights both current and future applications of EVs, including: 🌱 𝗣𝗹𝗮𝗻𝘁-𝗯𝗮𝘀𝗲𝗱 𝗘𝗩 𝗶𝘀𝗼𝗹𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 for sustainable therapeutics 🧪 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗼𝗿𝘀 for small EV production 🧬 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗲𝘅𝗼𝘀𝗼𝗺𝗲 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 in tumor immunology and targeted therapies 🔬 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗘𝗩 𝗯𝗶𝗼𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗶𝗻𝗴 to enhance cancer diagnostics and treatments Dive into the world of extracellular vesicles and discover how these tiny particles have the potential to revolutionize diagnostics and therapeutics for human diseases. 📥  𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗻𝗼𝘄 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/eWT6qzCW #LifeSciences #Oncology #Biotechnology #BioPharma

Exciting Advances in CAR T Cell Therapy! A recent study in Nature Biotechnology unveils a promising strategy to enhance the efficacy and persistence of CAR T cells using CAR enhancers (CAR-Es). This innovative approach could revolutionize cancer treatment by overcoming current limitations of CAR T cell therapy. What’s New? CAR-E boosts CAR T cell activity and longevity by fusing the CAR T cell antigen with a low-affinity IL-2. Enhances T cell activation and antitumor activity without additional genetic modifications. Why It Matters: Improved persistence of CAR T cells could lead to longer-lasting remissions for cancer patients. This advancement opens doors for broader applications and more effective treatments. Read more about this breakthrough https://lnkd.in/gd-j2RZd #Immunotherapy #CARTCell #Biotechnology #CancerTreatment #Innovation

Two of our scientific leaders will be at #ASGCT2024 next week to present their latest work.  Mark Landon will present findings/data on #AB2100, our #celltherapy being studied as a potential treatment for #kidneycancer in a phase 1/2 trial. The investigative medicine's unique logic gating technology, potentially enables it to target clear cell, renal cell carcinoma tumors with minimal damage to healthy surrounding tissues. Glenn Wozniak will present on T cell exhaustion, a major hurdle in immunotherapy development. By leveraging CRISPR/Cas9-based screening paired with single-cell readouts, our researchers identified combinations of genetic perturbations that can prevent T cell exhaustion and enhance T cell function in preclinical studies. #CARTcells #Immunotherapy #CRISPR #CancerResearch

PARP and DDR Pathway Drug Discovery Exploring cancer therapy through DNA damage response (DDR) research? DDR is key for DNA repair and preventing genomic instability. Defects in this pathway can lead to cancer. Targeting kinases like WEE1, DNA PK, ATM/ATR, and PARP proteins is crucial in drug discovery. Promega offers advanced assays and technologies for PARP/DDR pathway research, including target engagement and cell health assays. Want to learn more? Visit: https://bit.ly/3OQWwyU #kinases #PARP #assays

💡MEQ Innovations: Engineering Novel Proteins for Cancer Therapy 🧬 Explore the revolutionary MEQ and its application in creating novel proteins for cutting-edge technologies like monoclonal antibodies. This video dives deep into how MEQ-driven advancements are reshaping cancer treatment, focusing on the engineering of precision medicines that target cancer cells while sparing healthy tissue. From gene cloning and protein expression to sophisticated purification techniques and antibody optimization, witness the transformative power of MEQ in biotechnology and its profound impact on the future of healthcare. #MEQ #McGintyEquation #NovelProteins #MonoclonalAntibodies #CancerTreatment #PrecisionMedicine #Biotechnology #GeneCloning #ProteinExpression #AntibodyConjugation #BioreactorTechnology #ProteinPurification #Immunotherapy #ClinicalTrials #MolecularMedicine #PharmaceuticalSciences #TargetedTherapy #HealthScience #Bioprocessing